Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16)-Reference-Cited by-同舟云学术

Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16)

Published:2020-03 Issue: Volume:127 Page:183-190
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Park Inkeun^ORCID,Kim Bong-Seog,Lim Ho Yeong,Kim Hee-Jun,Lee Hyo Jin^ORCID,Choi Yoon Ji,Park Kyong Hwa,Lee Kyung Hee,Yoon Shinkyo,Hong Bumsik,Hong Jun Hyuk,Ahn Hanjong^ORCID,Lee Jae Lyun^ORCID

Funder

Asan Institute for Life Sciences, Asan Medical Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference16 articles.

1. Evolving treatment of advanced urothelial cancer;Sridhar;J Oncol Pract,2017

2. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000

3. Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

4. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy;Galsky;J Clin Oncol,2011

5. Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma;Clinical Cancer Research;2024-03-05

2. Gemcitabine/Nab‐Paclitaxel versus Gemcitabine/Carboplatin for Advanced Urothelial Carcinoma;BJU International;2023-11-27

3. Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC);Current Oncology;2023-03-26

4. Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5;Cancer Research and Treatment;2021-10-15

5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial;The Lancet Oncology;2021-06